Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction - PubMed (original) (raw)
Comparative Study
Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction
F Van de Werf et al. N Engl J Med. 1984.
Abstract
Tissue-type plasminogen activator is a naturally occurring, clot-selective activator of fibrinolysis. We recently reported that human tissue-type plasminogen activator isolated from a Bowes-melanoma-tissue-culture supernate lysed coronary thrombi in dogs without depleting circulating fibrinogen or alpha 2-antiplasmin, in contrast to the case with streptokinase and urokinase. In the present study coronary thrombolysis, confirmed angiographically, was induced within 19 to 50 minutes with intravenous or intracoronary tissue-type plasminogen activator in six of seven patients with evolving myocardial infarction. Circulating fibrinogen, plasminogen, and alpha 2-antiplasmin were not depleted by this agent, in contrast to the case in the two patients subsequently given streptokinase. In the one patient in whom lysis was not inducible with tissue-type plasminogen activator, it was also not inducible with streptokinase. These observations indicate that clot-selective coronary thrombolysis can be induced in patients with evolving myocardial infarction by means of tissue-type plasminogen activator, without concomitant induction of a systemic lytic state. Definition of its therapeutic benefit must await greater availability of the agent and the performance of appropriate clinical trials.
Similar articles
- Coronary thrombolysis with clot-selective plasminogen activators.
Collen D, Bounameaux H. Collen D, et al. Herz. 1986 Feb;11(1):9-15. Herz. 1986. PMID: 3082731 - Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
Collen D, Lijnen HR. Collen D, et al. Thromb Haemost. 1995 Jul;74(1):167-71. Thromb Haemost. 1995. PMID: 8578451 Review. - [New thrombolytic agents in myocardial infarction].
Charbonnier B, Lang M, Brochier M. Charbonnier B, et al. Arch Mal Coeur Vaiss. 1987 Nov;80(12):1785-91. Arch Mal Coeur Vaiss. 1987. PMID: 3128222 Review. French.
Cited by
- Don't go breakin' my heart: cardioprotective alterations to the mechanical and structural properties of reperfused myocardium during post-infarction inflammation.
Pearce DP, Nemcek MT, Witzenburg CM. Pearce DP, et al. Biophys Rev. 2023 Jun 10;15(3):329-353. doi: 10.1007/s12551-023-01068-3. eCollection 2023 Jun. Biophys Rev. 2023. PMID: 37396449 Free PMC article. Review. - Statins and Hemostasis: Therapeutic Potential Based on Clinical Evidence.
Prado Y, Aravena D, Llancalahuen FM, Aravena C, Eltit F, Echeverría C, Gatica S, Riedel CA, Simon F. Prado Y, et al. Adv Exp Med Biol. 2023;1408:25-47. doi: 10.1007/978-3-031-26163-3_2. Adv Exp Med Biol. 2023. PMID: 37093420 Review. - Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy.
Jasmiad NB, Abd Ghani RB, Agarwal R, Ismail ZB, Mohd Abdullah AA, Idorus MY. Jasmiad NB, et al. BMC Ophthalmol. 2022 Sep 3;22(1):357. doi: 10.1186/s12886-022-02550-4. BMC Ophthalmol. 2022. PMID: 36057550 Free PMC article. - Four Decades of Ischemic Penumbra and Its Implication for Ischemic Stroke.
Yang SH, Liu R. Yang SH, et al. Transl Stroke Res. 2021 Dec;12(6):937-945. doi: 10.1007/s12975-021-00916-2. Epub 2021 Jul 5. Transl Stroke Res. 2021. PMID: 34224106 Free PMC article. Review. - Tenecteplase Thrombolysis for Acute Ischemic Stroke.
Warach SJ, Dula AN, Milling TJ Jr. Warach SJ, et al. Stroke. 2020 Nov;51(11):3440-3451. doi: 10.1161/STROKEAHA.120.029749. Epub 2020 Oct 13. Stroke. 2020. PMID: 33045929 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical